Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

Company Overview

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories. These products support the detection and quantification of biomarkers ranging from infectious disease antigens to tumor-associated proteins. Qualigen’s diagnostic portfolio is sold to reference laboratories, hospital systems and point-of-care facilities across North America, Europe and select markets in Asia.

Qualigen BioTherapeutics is focused on developing a pipeline of antibody-based and cell-based immunotherapies targeting both hematologic and solid tumors. Its preclinical programs include monoclonal antibodies directed against validated cancer antigens as well as engineered cell therapies designed to enhance tumor recognition and cytotoxicity. The company applies proprietary protein conjugation and high-throughput screening platforms to advance candidates from lead identification through IND-enabling studies.

Key Stats

• Today's Range: $1.40 to $1.44
• 50-Day Range: $0.96 to $1.57
• 52-Week Range: $1.61 to $8.81
• Volume: 39,479 shs
• Average Volume: 1.52 million shs
• Market Capitalization: $2.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Qualigen Therapeutics Stock Analysis - MarketRank™

Qualigen Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Qualigen Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Qualigen Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Qualigen Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Qualigen Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for QLGN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Qualigen Therapeutics does not currently pay a dividend.

Dividend Growth

Qualigen Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Qualigen Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Qualigen Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.80% of the stock of Qualigen Therapeutics is held by insiders.

Percentage Held by Institutions

3.18% of the stock of Qualigen Therapeutics is held by institutions.

QLGN Stock Analysis - Frequently Asked Questions

How have QLGN shares performed this year?

Qualigen Therapeutics' stock was trading at $2.34 at the beginning of 2026. Since then, QLGN shares have decreased by 38.5% and is now trading at $1.44.

How were Qualigen Therapeutics' earnings last quarter?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced its quarterly earnings results on Friday, November, 14th. The company reported ($4.68) earnings per share (EPS) for the quarter.

When did Qualigen Therapeutics' stock split?

Shares of Qualigen Therapeutics reverse split before market open on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Qualigen Therapeutics IPO?

Qualigen Therapeutics (QLGN) raised $44 million in an initial public offering on Friday, June 19th 2015. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share.

How do I buy shares of Qualigen Therapeutics?

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Qualigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 11/14/2025
• Today: 5/08/2026
• Next Earnings (Estimated): 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QLGN
• CIK: 1460702
• Web: www.qualigeninc.com
• Phone: (760) 918-9165
• Fax: N/A
• Employees: 50
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($7.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -202.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.71
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.35

Miscellaneous

• Outstanding Shares: 1,695,000
• Free Float: 1,664,000
• Market Cap: $2.44 million
• Optionable: Not Optionable
• Beta: 0.24